News und Analysen

In the early days of the COVID-19 pandemic, Novavax (NASDAQ: NVAX) took center stage. The biotech company became one of the first to enter clinical trials with a coronavirus vaccine candidate. And

Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a

Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a

Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q1 2023 Earnings CallMay 09, 2023, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

MacroGenics (NASDAQ: MGNX)Q1 2023 Earnings CallMay 09, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Agenus (NASDAQ: AGEN)Q1 2023 Earnings CallMay 09, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit

Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released

Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals; and Auvelity, an

Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio

Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio

Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio

Image source: The Motley Fool.

Axsome Therapeutics (NASDAQ: AXSM)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S&P 500 Health Care Sector Index has dropped 1.7%. What's interesting

Medtronic (NYSE: MDT) is on a roll in more than one way. The medical device giant is beating the S&P 500 since the start of 2023. The company also continues to strengthen its portfolios, winning

Are you looking for underappreciated growth stocks that can deliver big gains? Try starting your search in the rapidly growing industry for minimally invasive cosmetic procedures.

The global market

If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of